GFM
NBIX icon

GF Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

GF Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$295K Buy
2,240
+282
+14% +$37.4K ﹤0.01% 254
2025
Q4 		$278K Sell
1,958
-176
-8% -$25.5K ﹤0.01% 261
2025
Q3 		$300K Sell
2,134
-459
-18% -$62.2K 0.01% 255
2025
Q2 		$326K Hold
2,593
– – 0.01% 283
2025
Q1 		$287K Buy
2,593
+467
+22% +$59.2K 0.01% 291
2024
Q4 		$290K Buy
+2,126
New +$263K 0.01% 258

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GF Fund Management's NBIX Position: Q1 2026 in Review

GF Fund Management increased its Neurocrine Biosciences (NBIX) stake by 14% in Q1 2026, buying an estimated $37.4K and bringing the position to 2,240 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #254.

GF Fund Management first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. The position peaked at $326K in Q2 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • GF Fund Management held 2,240 shares of Neurocrine Biosciences worth $295K as of Q1 2026.
  • GF Fund Management bought 282 Neurocrine Biosciences shares in Q1 2026, an estimated $37.4K.
  • Neurocrine Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #254 holding.
  • GF Fund Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Neurocrine Biosciences position peaked at $326K in Q2 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.